162 results
Page 5 of 9
8-K
EX-99.1
y6t16t91fo 01bz
9 Dec 19
Agios EstablishesProof-of-Concept for Mitapivat inNon-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results
4:02pm
8-K
EX-99.3
fz4djm qt
9 Dec 19
Agios EstablishesProof-of-Concept for Mitapivat inNon-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results
4:02pm
8-K
EX-99.1
hh7znj3n73fpv27x lr
22 Nov 19
Other Events
5:01pm
8-K
EX-99.1
dkwjztwraron2
8 Nov 19
Agios Announces Pricing of $256 Million Public Offering of Common Stock
4:57pm
8-K
EX-99.1
7y7961fpxmve7jhgy
31 Oct 19
Agios Reports Business Highlights and Third Quarter 2019 Financial Results
7:39am
8-K
EX-99.1
w1s30vl6f4 ob2juf7
28 Oct 19
Agios Presents Data from Single Agent Dose-Escalation Arm of Phase 1 Study ofAG-270, a MAT2A Inhibitor, in Patients withMTAP-Deleted Tumors
7:20am
8-K
EX-99.1
lgz8btov2 38yul48
30 Sep 19
Other Events
11:13am
8-K
EX-99.1
ynapxv6eah
4 Sep 19
Other Events
5:05pm
8-K
EX-99.1
ew95p3j
1 Aug 19
Agios Reports Business Highlights and Second Quarter 2019 Financial Results
7:29am
8-K
EX-99.1
5ihy4jhlyb38c6
3 Jun 19
Other Events
4:02pm
8-K
EX-99.1
htrlshhsv4zwbuu
15 May 19
Achieved its Primary Endpoint in Previously Treated IDH1 Mutant Cholangiocarcinoma
4:13pm
8-K
EX-99.1
kgelua1
2 May 19
Other Events
3:24pm
8-K
EX-99.1
i4cvkxnwb9
2 May 19
Agios Reports Business Highlights and First Quarter 2019 Financial Results
7:24am
8-K
EX-99.1
zihia2c3hvayc9f
14 Feb 19
Agios Reports Fourth Quarter and Full Year 2018 Financial Results
7:16am
8-K
EX-99.1
w9j12ovtir
7 Jan 19
Agios Highlights Key 2019 Initiatives to Broaden Potential for Late-Stage Cancer and Rare Genetic Disease Programs to Build Long-Term Value
7:48am